Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dongsung Pharmaceutical Co., Ltd. (002210:KRX), powered by AI.
Dongsung Pharmaceutical Co., Ltd. is currently trading at ₩973. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Dongsung Pharmaceutical Co., Ltd. on Alpha Lenz.
Dongsung Pharmaceutical Co., Ltd.'s P/E ratio is -3.6.
“Dongsung Pharmaceutical Co., Ltd. trades at a P/E of -3.6 (undervalued) with modest ROE of -65.5%.”
Ask for details →Dongsung Pharmaceutical Co., Ltd. is a renowned pharmaceutical company involved in the research, development, manufacturing, and distribution of health and wellness products. The company's primary function is to enhance healthcare by providing access to a wide range of pharmaceuticals and over-the-counter medical solutions. Dongsung Pharmaceutical is particularly known for its focus on skincare, cosmetics, and dermatological products, which cater to both individual consumers and healthcare institutions. The company leverages advanced biotechnological research to develop innovative treatments that address various skin conditions and health concerns. Its products are distributed through an extensive network covering domestic and international markets, contributing significantly to the pharmaceutical sector. Based in South Korea, Dongsung Pharmaceutical plays a strategic role in the healthcare industry by supporting the delivery of accessible medicine and healthcare services across global markets. Through its continuous investment in R&D, the company sustains its competitive edge and maintains a commitment to advancing global health outcomes.
“Dongsung Pharmaceutical Co., Ltd. trades at a P/E of -3.6 (undervalued) with modest ROE of -65.5%.”
Ask for details →Dongsung Pharmaceutical Co., Ltd. (ticker: 002210) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 298 employees. Market cap is $93.8B.
The current price is ₩973 with a P/E ratio of -3.64x and P/B of 4.01x.
ROE is -65.53% and operating margin is -11.61%. Annual revenue is $87.2B.